Wound-healing peptide discussions are often dominated by two names: BPC-157 and TB-500. In practice, researchers also evaluate a broader set of candidates depending on tissue target, inflammation profile, antimicrobial needs, and handling constraints.
This page now uses a stricter evidence rule: peptides with directly verified wound-healing citations are separated from names that remain part of the broader discussion but still need stronger source review before they should be treated as well-supported leads.
10 Commonly Discussed Candidates
BPC-157 TB-500 GHK-Cu Thymosin Alpha-1 LL-37 KPV Ipamorelin CJC-1295 Semax Selank
Better-Supported Candidates in This Revision
Peptide Primary Research Focus Relative Stability Evidence Confidence BPC-157 Soft tissue, GI, repair signaling Medium Medium GHK-Cu Skin/repair signaling, remodeling Medium Medium LL-37 Antimicrobial and immune modulation Fragile Medium KPV Anti-inflammatory signaling Medium Medium
Candidates Still Requiring Stronger Direct Citation Review
TB-500 / Thymosin Beta-4 fragment Thymosin Alpha-1 Ipamorelin CJC-1295 Semax Selank
These names remain on the watchlist because they appear frequently in peptide-research discussions, but this article does not treat them as equivalently supported wound-healing leads without a finalized direct citation set.
BPC-157 vs TB-500: Practical Notes
BPC-157 is commonly selected for localized or connective-tissue-centered workflows TB-500 is often discussed for broader systemic tissue-repair concepts, but this article now treats that discussion as lower-confidence until the direct citation set is finalized Both require disciplined handling, consistent tracking, and realistic confidence labeling
Handling Checklist for Research Quality
Keep storage conditions consistent Track solvent type and reconstitution date Avoid overinterpreting early trend changes Review peptide-specific confidence levels before conclusions
Internal Links
Compare compound profiles in Peptide Database Estimate potency trajectory in the Potency Calculator Track multiple vials in Multi-Vial Dashboard
Key References & Evidence
Sikiric P, et al. “Stable Gastric Pentadecapeptide BPC 157 and Wound Healing.” Front Pharmacol. 2021;12:627533. PMID 34267654 — Comprehensive BPC-157 wound healing review.
Chang CH, et al. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” J Appl Physiol. 2011;110(3):774-80. PMID 21030672 — Tendon repair mechanism.
Sikiric P, et al. “Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.” Curr Pharm Des. 2011;17(16):1612-32. PMID 21548867 — BPC-157 gastric stability and GI applications.
GHK-Cu wound healing: Pickart and Margolina — Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (PMID 29986520); Wang et al. — GHK-Cu-liposomes accelerate scald wound healing in mice (PMID 28370978).
LL-37 wound healing: Miranda et al. — LL-37 cream in diabetic foot ulcer healing (PMID 37480520); Yang et al. — LL-37 hydrogel in mouse deep tissue injury healing (PMID 32321591).
KPV wound healing / repair context: Zhao et al. — KPV and EGF film improved diabetic wound repair in mice (PMID 36240893); Bonfiglio et al. — KPV effects on corneal epithelial wound healing (PMID 16965771); Bohm and Luger — review of melanocortin peptides in cutaneous wound healing (PMID 30661264).
TB-500 / Thymosin Beta-4: This revision does not treat TB-500 as source-validated for wound-healing ranking because a direct citation set was not finalized during review. It remains a watchlist item, not a verified evidence peer to BPC-157 in this article.
Stability classifications: ICH Q1A(R2) + ICH Q5C. Decay rates are [Model Estimates — PeptideClock].